Source comparison
CJC-1295 No DAC vs With DAC: Timeline Comparison
Onset of IGF-1 Elevation 2–4 hours post-injection 24–48 hours post-injection No DAC provides immediate control; with DAC requires loading period Duration of Effect per Dose 12–18 hours 6–8 days No DAC mimics natural pulsatility; with DAC creates sustained back
This comparison does not assign a generated winner or score.
- Onset of IGF-1 Elevation
- 2–4 hours post-injection
- 24–48 hours post-injection
- No DAC provides immediate control; with DAC requires loading period
- Duration of Effect per Dose
- 12–18 hours
- 6–8 days
- No DAC mimics natural pulsatility; with DAC creates sustained background elevation
- Dosing Frequency
- 1–3× daily
- 1–2× weekly
- No DAC requires consistent administration; with DAC simplifies protocol adherence
- Peak IGF-1 Amplitude
- 200–350 ng/mL (dose-dependent)
- 250–400 ng/mL (cumulative)
- No DAC produces acute pulses; with DAC maintains steady-state elevation
- Research Timeline to Measurable Outcomes
- 4–6 weeks (twice-daily protocol)
- 6–8 weeks (weekly protocol)
- No DAC allows faster titration; with DAC shows delayed but sustained response
- Desensitisation Risk
- Moderate (if dosed <4 hours apart)
- Low (infrequent dosing)
- No DAC requires spacing; with DAC avoids receptor downregulation
- The DAC (Drug Affinity Complex) modification extends half-life from 30 minutes to approximately 6–8 days by binding to serum albumin, creating a slow-release reservoir. Research models using CJC-1295 with DAC report more stable IGF-1 curves with less peak-to-trough variation, but the trade-off is reduced controllability. If adverse effects appear, the compound remains active for days. No DAC clears within 24 hours, allowing researchers to halt administration and return to baseline quickly. Protocol selection depends on research objectives: acute intervention studies favour No DAC; long-duration observational studies favour with DAC.